FindMyKOL
Clinical trialNCT07659782RecruitingPhase 2Interventional

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

NCT07659782 is a phase 2 interventional trial sponsored by Verastem, Inc.. As of 21 Nov 2026, it is recruiting participants. It studies VS-7375 in Non-Small Cell Lung Cancer. The registry lists an enrollment of 105 participants at 26 sites in 4 countries. The registry lists a start date of 22 Jul 2026 and a primary completion date of 30 Jun 2027. One of its registered investigators has a FindMyKOL profile.

SponsorVerastem, Inc.Enrollment105Non-Small Cell Lung Cancer
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT07659782
FieldValue
Registry IDNCT07659782
StatusRecruiting
PhasePhase 2
Study typeInterventional trial
Lead sponsorVerastem, Inc.
Enrollment105
Registered sites26
Countries4
ConditionsNon-Small Cell Lung Cancer
DrugsVS-7375
Start22 Jul 2026
Primary completion30 Jun 2027
Study completion31 Dec 2028
Last update posted17 Nov 2026
Other registry IDsEU-CTR / CTIS (EudraCT) 2026-526472-23-00

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will assess the safety and efficacy of VS-7375 alone in patients with metastatic KRAS G12D-mutated Non-Small Cell Lung Cancer

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

26 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Arizona, United States1 site, 1 recruiting
  • Honorhealth Research Institute

    Scottsdale

    Frank Tsai, MD
    Recruiting
California, United States3 sites, 3 recruiting
  • Cedars-Sinai Medical Center

    Los Angeles

    Karen Reckamp, MD
    Recruiting
  • Start la

    Los Angeles

    Navid Hafez, MD
    Recruiting
  • Valkyrie Clinical Trials

    Los Angeles

    David Berz, MD
    Recruiting
Colorado, United States1 site, 1 recruiting
  • University of Colorado Cancer Center

    Aurora

    Tejas Patil, MD
    Recruiting
Florida, United States3 sites, 3 recruiting
  • Brcr Global - Coral Springs

    Coral Springs

    Sumit Sawhney, MD
    Recruiting
  • Brcr Global- Tamarac

    Tamarac

    Andrew Schneider, MD
    Recruiting
  • Moffit Cancer Centre

    Tampa

    Andreas Saltos, MD
    Recruiting
Georgia, United States1 site, 1 recruiting
  • Emory Winship Cancer Institute

    Atlanta

    Jennifer Carlisle, MD
    Recruiting
Illinois, United States1 site, 1 recruiting
  • University of Chicago

    Chicago

    Marina Garassino, MD
    Recruiting
New Jersey, United States1 site, 1 recruiting
  • Start New Jersey

    East Brunswick

    Bruno Fang, MD
    Recruiting
New York, United States2 sites, 2 recruiting
  • Memorial Sloan Kettering Cancer Center

    New York

    Kathryn Arbour, MD
    Recruiting
  • Nyu

    New York

    Rajwanth Veluswamy, MD
    Recruiting
North Carolina, United States1 site, 1 recruiting
  • University of North Carolina at Chapel Hill

    Chapel Hill

    Shetal Patel, MD, PhD
    Recruiting
Texas, United States2 sites, 2 recruiting
  • Start Fort Worth

    Fort Worth

    Salwan Almutar, MD
    Recruiting
  • Md Anderson Cancer Center

    Houston

    Marcelo Negrao, MD
    Recruiting
Utah, United States1 site, 1 recruiting
  • University of Utah

    Salt Lake City

    Matthew Gumbleton, MD
    Recruiting
Virginia, United States2 sites, 2 recruiting
  • University of Virginia

    Charlottesville

    Richard Hall, MD
    Recruiting
  • Virginia Cancer Specialists

    Fairfax

    Alexander Spira, MD
    Recruiting
Australia4 sites, 4 recruiting
  • Chris O'Brien Lifehouse

    Camperdown, New South Wales

    Malinda Itchins, BMedSci, MBBS, FRACP, PhD
    Recruiting
  • Macquarie University Hospital

    Sydney, New South Wales

    John Park, BSc MBBS MPH FRACP PhD
    Recruiting
  • Icon Cancer Centre South Brisbane

    Brisbane, Queensland

    Jermaine Coward, BSc, MBBS, MRCP, FRACP, PhD
    Recruiting
  • Monash Health

    Clayton, Victoria

    Surein Arulananda, MBBS BMedSci PhD FRACP
    Recruiting
Puerto Rico2 sites, 2 recruiting
  • Brcr Global- San Juan

    San Juan

    Alexandra Deya, MD
    Recruiting
  • Brcr Global- Yauco

    Yauco

    Maryknoll De La Paz, Md
    Recruiting
Belgium1 site, 1 recruiting
  • Chu Ucl Namur - Sainte-Elisabeth

    Namur

    Jean-Charles Goeminne, MD
    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew York: 2 sites, 2 recruitingNY2MassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinois: 1 site, 1 recruitingIL1IndianaINOhioOHPennsylvaniaPANew Jersey: 1 site, 1 recruitingNJ1ConnecticutCTCalifornia: 3 sites, 3 recruitingCA3NevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginia: 2 sites, 2 recruitingVA2MarylandMDDelawareDEArizona: 1 site, 1 recruitingAZ1Utah: 1 site, 1 recruitingUT1Colorado: 1 site, 1 recruitingCO1KansasKSArkansasARTennesseeTNNorth Carolina: 1 site, 1 recruitingNC1South CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgia: 1 site, 1 recruitingGA1HawaiiHITexas: 2 sites, 2 recruitingTX2Florida: 3 sites, 3 recruitingFL3District of ColumbiaDC
Fewer sitesMore sites

Outside the United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT07659782

Each answer restates registry values shown on this page.

What is NCT07659782?

NCT07659782 is a phase 2 interventional trial sponsored by Verastem, Inc.. It studies VS-7375 in Non-Small Cell Lung Cancer.

Is NCT07659782 recruiting?

As of 21 Nov 2026, it is recruiting participants. 26 of its 26 sites list their own status as recruiting.

Where does NCT07659782 run?

The registry lists 26 sites in 4 countries. Most sites are in these countries: United States (19), Australia (4) and Puerto Rico (2).

Which drugs does NCT07659782 study?

The registered drug and biological interventions are VS-7375.

When is NCT07659782 expected to complete?

The registry lists a primary completion date of 30 Jun 2027 and a study completion date of 31 Dec 2028. The sponsor last updated the record on 17 Nov 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.